Previous studies have shown that FBXL19-AS1 was significantly increased in breast cancer (13, 14, 30), lung cancer (15, 16, 31), osteosarcoma (17), colorectal cancer (18), cervical cancer (32), and glioma (33), and participated in the migration, proliferation and survival of tumor cells. Here, FBXL19 is linked to central nervous system cancer.